Background
Introduction/Background 1
Major Depressive Disorder (MDD) is a common and frequently recurrent mood disorder. MDD as a 2 recurrent disorder comprises at two or more major depressive episodes (MDEs).
4
This psychiatric disorder is characterized by symptoms interfering with the daily life of patients, such 5 as lack of enjoyment in activities, feelings of sadness, guilt, anxiety, and recurrent thoughts of death 6 and suicide (1) . It may also harm the wellbeing of family members, including children. Being the child 7 of a depressed parent carries a greatly increased risk of suffering from depression for the child 8 involved. As many as 40 percent of the children of depressed parents will suffer from depression 9 before 20 years of age (1, 2) . The number of adult patients experiencing a moderate-to-severe MDE (5), hospital admissions (6) , and impaired work productivity (7).
14 Therefore, the need to achieve early control in MDD highlights the importance of having effective and 15 well-tolerated treatment options available in the event of inadequate response to a first treatment. In
16
case of absent or minimal response after 8 weeks of treatment, the National Institute for Health and
17
Care Excellence (NICE) CG90 guidelines recommend switching to another antidepressant, newer-18 generation or different class (8, 9) . The NICE guidelines as published by NICE, which is the main 19 health technology assessment body in the UK, provide evidence-based guidance, advice and 20 information services for health, public health and social care professionals. The NICE CG90
21
guidelines cover identification and management of depression in adults, in both the primary and 22 secondary care settings in the UK.
23
MDD is associated with heterogeneity in terms of both patients and treatments. Therefore, a strict 24 treatment strategy is unlikely to be optimal, particularly at latter lines of therapy. Due to the recurrent 25 nature of depression, in addition to the high treatment failure rate attributable to inadequate efficacy or 26 intolerability, clinicians aim to match the treatment to the individual, taking into account their treatment 27 and family history, where applicable. This is an approach that is supported by both NICE CG90 
33
Vortioxetine is an efficacious and well-tolerated, once-daily, orally-administered treatment option for 34 MDD (10) . It is an antidepressant with a novel mechanism of action that is thought to work through a 35 combination of serotonin reuptake inhibition and modulation of serotonin receptor activity (10) . In 36 addition, pre-clinical and clinical data provide evidence to demonstrate the effect of vortioxetine on 37 cognitive symptoms of MDD (11, 12) . Vortioxetine offers significant and clinically relevant 
44
Vortioxetine has been recently approved by NICE as an option for treating MDE in adults whose 45 condition has responded inadequately to two antidepressants within the current episode. Detail on the 46 process can be found in the NICE technology appraisal guidance for vortioxetine (TA367) and the
47
Evidence Review Group critique in Lomas 2016. (14, 16) 
48
This paper details the economic model and analysis that was considered in the NICE evaluation of 49 vortioxetine for patients receiving third-line treatment in the UK.
50

Methods 51
The population consists of patients who have responded inadequately to two antidepressants within 52 the current episode; referring to third-line in the treatment pathway for their MDE. This includes
53
patients who have experienced a lack of efficacy or/and intolerability to their previous two treatments.
54
The model required making a number of assumptions, which are explicitly described in this section 55 and in the 'limitations' section at the end of this manuscript.
58
Model structure
59
In order to ensure the model structure was reflective of UK clinical practice, a comprehensive review 60 of both national and local guidelines, along with current clinical practice through both questionnaires
61
and an advisory board have been undertaken. The structure has been adapted from a model 62 presented in Trivedi et al. 2004 (17) , a review on existing models in the NICE depression guidelines 63 (9) and a model developed by The Dental and Pharmaceutical Benefits Agency (TLV ) in Sweden (1) . 64
Patients were diagnosed using the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) 65 criteria. The DSM diagnostic criteria for MDD are well recognised and widely used in trial settings,
66
with DSM IV being employed in the trials of vortioxetine (18) .
67
The model (available on request) consisted of both a decision tree and a Markov component (Figure 
81
that switch at 8 weeks due to no response was reflective of practice (19) . Furthermore, a previous 82 cost-utility analyses based on the STAR*D trial shows that switching antidepressants after insufficient 83 response increased remission rates (20) . A change of treatment at 4 weeks was assumed for patients Page 6 withdrawing due to adverse events, based on internally sourced data, where the majority of patients 85 who stopped treatment due to adverse events withdrew by 4 weeks (21) . During the acute phase 86 patients incurred the risk of treatment specific short-term AEs (sexual AEs, dry mouth, nausea, 87 sweating, headache, somnolence, diarrhoea, insomnia and dizziness) which were independent of 88 each other.
89
The maintenance phase of treatment was considered to be 6 months. This was in line with the 
97
The overall time horizon was 24 months. This allowed for representation of patients with a history of 98 recurrent episodes.
99
Comparators
100
In the UK, the initial recommended treatment is a generic selective serotonin reuptake inhibitor 
126
However, the heterogeneity within the included studies may limit the robustness of conclusions. 
162
The response rate of 37.1% was calculated as one minus the probability of remission and of no 163 response ( Table 1 ). The rates of withdrawal due AEs were subtracted directly from the proportion of The efficacy values at 12 weeks were calculated based on conditional probabilities observed in the 168 REVIVE study. Patients in the response health state at 8 weeks had a 59.92%, 32.14% and 8.33% 169 probability of being in remission, response and no response at 12 weeks respectively (Table 1) .
170
These values were assumed to be applied to all comparators in the model due to lack of individual 171 patient data for some comparators; and were consistent with the approach proposed by NICE.
172
Similarly, relapse and remission at subsequent lines of treatment were also not considered to be 
175
Patients who achieve recovery face a two-month probability of recurrence (0.44%; See
176
supplementary material for equations). This value was derived from a publication by Hardeveld et al.
177
(2013). (28) The estimate was taken from a 10-year recurrence probability that was adjusted to reflect 178 the two month cycles of the model.
179
Furthermore, spontaneous recovery was considered for the model. However, it was not included as it 180 would require further assumptions, which would add complexity to the model and, at the same time, it 181 would not change the overall conclusion of the study. 
182
186
Tolerability data for short-term events (Table 2) 
Results 235
The ICERS based on pairwise analyses versus vortioxetine, and incremental ICERs are presented in 236 
244
According to UK guidelines, a treatment with a different mechanism of action should be considered at 245 third-line. Therefore, the results excluding SSRIs provided further evidence for the cost-effectiveness 246 of vortioxetine as a third-line of treatment due to its dominance over venlafaxine and duloxetine. 
257
This resulted in a dominant ICER against all comparators except for agomelatine. However, the ICER
258
for agomelatine compared to vortioxetine showed it not to be a cost-effective treatment option at 259 £332,296. 
268
The probabilistic sensitivity analysis (PSA) which explores the robustness in the results demonstrated 
278
Vortioxetine has been recently approved by NICE as an option for treating MDE in adults whose 279 condition has responded inadequately to two antidepressants within the current episode. The base
280
case pair-wise analyses showed vortioxetine to be a cost-effective treatment versus citalopram,
281
escitalopram and sertraline when a NICE threshold of £20,000 -£30,000/QALY was considered.
282
Vortioxetine was a dominant strategy versus venlafaxine and duloxetine. For the comparison to 
295
An economic evaluation has been undertaken in Scotland comparing venlafaxine and duloxetine, the 
310
line. However, these changes have required some assumptions, particularly related to the data inputs.
311
It is also of great interest to consider the scenarios comparing primary and secondary care 
314
This can be explained by a better tolerability profile for vortioxetine leading to fewer patients switching
315
and thus avoiding the higher costs associated with management. According to UK clinical guidelines,
316
patients with a higher risk of relapse should continue on treatment for at least two years. The results
317
of the extended 22-month maintenance phase scenario provide evidence for vortioxetine as a cost- 
349
Conclusion 350
Vortioxetine is an antidepressant with a unique mechanism of action. It has been shown to be at least 
Supplementary Material
To allow for comparison across all the studies, the relevant results were presented based on odds ratios (OR) using vortioxetine as the reference. 
